Umecrine Cognition was founded as a subsidiary to Umecrine AB. Umecrine Cognition is developing pharmaceuticals against neurological disorders in the central nervous system, CNS that are caused by endogenous CNS-active steroids (GABA-steroids). Furthermore, is company active in development and commercialization of novel therapeutics to treat Hepatic Encephalopathy (HE) in patients with liver disease, a growing area with high unmet medical need. HE is a neurocognitive and neuropsychiatric complication, characterized by impaired cognitive and motor functions with symptoms ranging from disorientation through coma. We are developing pharmaceuticals to treat acute life-threatening HE and long-term maintenance in minimal HE caused by endogenous GABA-steroids.
Disclaimer: The content of the pages of this website is for your general information and use only. It is subject to change without notice. Neither we nor any third parties provide any warranty or guarantee as to the accuracy, timeliness, performance, completeness or suitability of the information and materials found or offered on this website for any particular purpose. You acknowledge that such information and materials may contain inaccuracies or errors and we expressly exclude liability for any such inaccuracies or errors to the fullest extent permitted by law. Your use of any information or materials on this website is entirely at your own risk, for which we shall not be liable. It shall be your own responsibility to ensure that any products, services or information available through this website meet your specific requirements.